An underground market for unapproved weight-loss drugs is being driven by TikTok fitness influencers and sellers on messaging platforms, according to new investigations.
Experimental Drug Gaining Traction Via Social Media
The experimental drug, which is still in clinical trials, is being promoted by online personalities for its supposed fat-burning effects. Followers are urged to message these profiles directly for source information, while also receiving promotional offers.
Active Trade on Messaging Platforms
Separately, a robust market exists on messaging services, where communities with numerous of members share comparison photos, injection guides and claims of next-day British shipping. Sellers promote the substance there before redirecting buyers to other platforms for purchases.
Learning About The Experimental Drug
Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist individuals reduce up to 25% of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.
Healthcare Experts Voice Worries
However, doctors and chemists have cautions that the distribution of what remains an unlicensed drug in the United Kingdom is worrisome and could result in users injecting substances of uncertain source.
Some professionals stated the popularity for the experimental drug could be linked to the rising cost of licensed weight loss treatments such as Mounjaro.
Regulatory Status and Implementation
Selling the unapproved drug on social media or Telegram is illegal in the UK, as it is an unapproved drug that must not be marketed or distributed for human use under the Human Medicines Regulations 2012.
Some influencers attempt to sidestep the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still violate pharmaceutical, advertising, and consumer laws, potentially leading to penalties, prosecution or imprisonment.
Platform Reaction and Content Removal
Based on the social media company, the service has taken down problematic material and prohibited associated keywords and query recommendations. The company said it was committed to maintaining the platform secure and investing in enhancing compliance measures.
Online Marketplace Activities
Investigations also found groups with up to 9,000 participants selling retatrutide using Telegram's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” immediately brings up groups with thousands of users, populated with images of slimming results, positive testimonials and step-by-step instructions for mixing or administering at home.
After moments of entering one group, a seller posted contact information, where the majority of purchases take place. The vendor provided an guidebook and promised delivery within 48 hours. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about body mass, medical conditions or past usage.
Product Details and Pricing
Inside these groups, posts display black plastic parcels with Royal Mail labels, stating to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”
Buyers can select between powder vials, mixed at residence with purified liquid, or pre-filled injectors usually priced at £160 for 20mg. When asked how long a injector should be used, vendors give contradictory answers ranging from a several days to “depends on your body”.
Platform Oversight and Safety Measures
A spokesperson for Telegram stated it actively monitored dangerous content on its platform including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“People are injecting materials they can’t verify. Although the research behind retatrutide is valid, these online products may not include what they claim,” stated a pharmacy expert, the director of pharmaceutical services at a pharmacy service.
A medical professional of an online medical service connected the increase in interest to recent price rises for approved weight-loss medications such as Mounjaro. “With costs rising, individuals are turning to online platforms. But counterfeit treatments are extremely dangerous. You cannot know what’s contained or whether the environment they were made in was sterile,” she said.
Her staff has already encountered individuals harmed by self-injection from unverified sources. “We understand the disappointment, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said Wyllie. “These substances could be impure or improperly measured.”
Manufacturer Statement
A representative from Eli Lilly said retatrutide was in phase 3 research studies and had not been reviewed or authorized by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a Lilly investigational product not yet approved … may subject patients to possibly significant health risks”.
